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The Zyxin/Ajuba family of cytosolic LIM domain-containing proteins has the potential to shuttle from sites
of cell adhesion into the nucleus and thus can be candidate transducers of environmental signals. To understand Ajuba’s role in signal transduction pathways, we performed a yeast two-hybrid screen with the LIM
domain region of Ajuba. We identified the atypical protein kinase C (aPKC) scaffold protein p62 as an Ajuba
binding partner. A prominent function of p62 is the regulation of NF-B activation in response to interleukin-1
(IL-1) and tumor necrosis factor signaling through the formation of an aPKC/p62/TRAF6 multiprotein signaling complex. In addition to p62, we found that Ajuba also interacted with tumor necrosis factor receptorassociated factor 6 (TRAF6) and PKC. Ajuba recruits TRAF6 to p62 and in vitro activates PKC activity and
is a substrate of PKC. Ajuba null mouse embryonic fibroblasts (MEFs) and lungs were defective in NF-B
activation following IL-1 stimulation, and in lung IKK activity was inhibited. Overexpression of Ajuba in primary MEFs enhances NF-B activity following IL-1 stimulation. We propose that Ajuba is a new cytosolic component of the IL-1 signaling pathway modulating IL-1-induced NF-B activation by influencing the assembly
and activity of the aPKC/p62/TRAF6 multiprotein signaling complex.
The LIM region and the PreLIM region have unique, nonoverlapping binding partners and as such have the potential to link
distinct proteins and/or functions. For example, Ajuba is recruited to cell-cell junctions in epithelial cells by virtue of the
LIM region interacting with ␣-catenin bound to the cytoplasmic tail of E-cadherin (27). The PreLIM region associates
directly with F-actin (27). As such, Ajuba is thought to contribute to the formation or stabilization of adherens junctions
by linking adhesive receptor to the actin cytoskeleton. Primary
skin keratinocytes from Ajuba null mice exhibit defects in
cell-cell adhesion ex vivo, and Ajuba null mice have defects in
skin wound healing (27).
Zyxin/Ajuba LIM proteins have also been implicated in the
regulation of other signaling pathways and cellular responses.
The PreLIM regions are proline rich and include putative SH3
recognition motifs, and the SH3 domains of Vav and Grb2
have been shown to interact with Zyxin and Ajuba, respectively
(12, 17). The functional significance of the Zyxin-Vav interaction is not clear, but the Ajuba-Grb2 interaction augments
serum-stimulated extracellular signal-regulated kinase (ERK)
activation in a Ras-dependent manner. Ajuba’s effect on ERK
can result in enhanced fibroblast proliferation and meiotic
maturation of Xenopus oocytes (12). Zyxin, LPP, and Trip6 but
not Ajuba and LIMD1 contain multiple FPPPP binding motifs
for EVH1 domains present in Ena/VASP proteins and may
serve to recruit these proteins to the leading edge and thereby
influence local actin assembly (36). Ajuba was recently found
to regulate Rac activity in migrating cells by influencing the
assembly of the p130Cas/Dock180 Rac guanine nucleotide exchange factor at sites of focal adhesions (34). As a result,
fibroblasts and keratinocytes from Ajuba null mice exhibit decreased cell motility (34). Accumulation of Ajuba in the nucleus of P19 multipotent embryonal carcinoma cells results in
spontaneous endodermal differentiation through a mechanism

The LIM domain is a tandem zinc finger structure mediating
protein interactions. The targets that LIM domains interact
with are multiple and quite varied in structure and function.
Proteins containing LIM domains (LIM proteins) are present
in the nucleus and cytoplasm, and some can shuttle between
the cytoplasm and nucleus. LIM proteins have been classified
based on sequence homology between LIM domains and their
overall protein organization (2). Some nuclear LIM proteins
contain homeodomains, while others are comprised of only
LIM domains (LIM-only proteins or LMO proteins). In the
nucleus, these proteins regulate transcription complex formation and function and thus cell lineage fate determination and
organ development (31). LIM-only proteins are also present in
the cytosol, but in addition, there are LIM domain-containing
protein kinases and complex type LIM domain-containing proteins (2). In the cytosol, these proteins contribute to the regulation of cytoskeletal organization, adhesion of cells to the
extracellular matrix and to other cells, and cell migration.
Of the complex cytosolic LIM proteins, the Zyxin/Ajuba
family is characterized by the presence of three homologous
LIM domains at their C terminus (LIM region) and distinct
N-terminal PreLIM region. Mammalian members include the
following: Ajuba (12), LIMD1 (20), LPP (33), Trip6 (46), and
Zyxin (5). While these proteins associate with cytoskeletal elements and are components of cell adhesive complexes, they
also shuttle in and out of the nucleus (19, 30, 32) and thus have
the potential for transducing signals from environmental cues.
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MATERIALS AND METHODS
Cells. Mouse embryonic fibroblasts (MEFs) were isolated as described previously (34) and maintained in Dulbecco’s minimal essential medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamate, and
antibiotics. HEK293 and HepG2 cells were maintained in DMEM–10% FCS
medium. HepG2.tet cell lines were maintained in DMEM medium containing
10% tetracycline-free FBS, 2 mM L-glutamate, and 5 g/ml blasticidin. MC3T3
osteoblast cell line clone E14 was maintained in ␣MEM supplemented with 10%
FBS, antibiotics, and 2 mM L-glutamate. Bone marrow-derived macrophages
(BMDM) were maintained in ␣MEM–10% FCS plus 100 ng/ml macrophage
colony-stimulating factor.
Antibodies and purified proteins. Ajuba antiserum has been described previously (19, 27). Zyxin polyclonal antibody was kindly provided by M. Beckerle
(University of Utah). Mouse monoclonal antibodies against p62 and rabbit
polyclonal antibodies against the p50 and p65 subunits of NF-B were from BD
Transduction Laboratories. TRAF6 and PKC rabbit polyclonal antibodies were
from Santa Cruz. M2AG (mouse monoclonal anti-Flag antibody immobilized on
agarose) and horseradish peroxidase (HRP)-conjugated monoclonal anti-Flag,
HRP-conjugated monoclonal anti-myc, and HRP-conjugated monoclonal antihemagglutinin (anti-HA) antibodies were all from Sigma (St. Louis, MO). Phospho-I〉, IB␣, phospho-ERK, ERK1, phospho-JNK, JNK1, phospho-p38, and
p38 polyclonal antibodies were all from Cell Signaling. Mouse IL-1␤, human
IL-1␤, and mouse TNF-␣ were from PerproTECH. Escherichia coli purified
lipopolysaccharide (LPS) was from Sigma. Purified human PKC was from Calbiochem. Ajuba, the PreLIM region of Ajuba, and the LIM region of Ajuba were
expressed in baculovirus and purified as described previously (27). Purified
proteins were dialyzed against immunoprecipitation (IP) buffer without NP-40
and concentrated with centrifugal filter units (Millipore). Protein aliquots were
stored at ⫺80°C until use.
Yeast two-hybrid screen. Competent yeast cells (strain AH109) containing the
plasmid pAS2-human Ajuba LIM region were transformed with human keratinocytes Matchmaker cDNA library (Clontech). Transformants (5 ⫻ 106) were
analyzed according to the manufacturer’s instructions. Positive colonies were
cured of the bait plasmid by segregation and the library plasmid rescued following transformation of XL1-Blue bacteria. Retransformation of yeast strain
AH109 with appropriate specificity controls was carried out to confirm all positives. Library plasmid cDNA inserts were sequenced.
Plasmids. Human Ajuba, PKC, and p62 cDNAs were PCR amplified from a
human keratinocyte cDNA library and subcloned into pCMV14 containing various N-terminal epitope tags: Flag, HA, or Myc. TRAF6 cDNA was kindly
provided by R. Arch (Washington University). The PreLIM and LIM regions of
Ajuba were PCR amplified and likewise subcloned. Human Ajuba, containing a
C-terminal Flag epitope, was subcloned into the tetracycline-inducible plasmid
pcDNA4 (drug resistance was changed from Zeocin to G418; Invitrogen).
TRAF6, p62, and PKC mutants were generated by PCR and subcloned. All
plasmids were verified by DNA sequencing and Western blot analysis of cell
extracts from HEK293 cells transfected with the respective plasmid. For plasmid
transfection of all cell lines, Transit LT-1 (Mirus) was used.

Tetracycline-inducible HepG2 cell lines. To generate the HepG2.tet repressor
cell line, cells were transfected with pcDNA6 containing the tetracycline (tet)
repressor (Invitrogen) and selected with 5 g/ml blasticidin, and clones were
isolated and confirmed by transfection of a tet-inducible green fluorescent protein plasmid. Control HepG2.tet- and HepG2.tet-Ajuba-F were obtained by
transfection of HepG2.tet with pcDNA4 or pcDNA4-Ajuba-Flag plasmids, respectively, and selected with 1.5 mg/mg G418 and 5 g/ml blasticidin; single
clones were obtained and tested for tet induction followed by Western blotting
for the presence of Ajuba-Flag.
IL-1, TNF, and LPS stimulation and cell fractionation. MEFs or BMDM (2 ⫻
106) were seeded in 100-mm dishes for 24 h and then washed and cultured in
serum-free DMEM for 2 h before addition of mouse IL-1␤ (10 ng/ml), mouse
TNF-␣ (10 ng/ml), or LPS (100 g/ml) for the times indicated. After stimulation,
cells were washed with ice-cold water and lysed with 200 l of hypotonic buffer
(20 mM HEPES [pH 7.5], 5 mM NaF, 1 mM sodium orthovanadate, 0.5 mM
EDTA, 1 mM dithiothreitol [DTT], and protease inhibitor cocktail from Sigma).
Samples were collected, NP-40 was added to 0.1%, and samples were vortexed
and centrifuged at 2,000 rpm for 5 min. The nuclear pellet was then extracted
with 20 l of hypertonic buffer (hypotonic buffer containing 400 mM NaCl), and
after centrifugation at 15,000 ⫻ g for 15 min, the supernatants were kept as
nuclear extract. Total cell lysates were prepared by lysing stimulated cells directly
with hypertonic buffer without fractionation and adding sodium dodecyl sulfate
(SDS) sample buffer. The protein concentration was determined with a Bio-Rad
protein assay kit. HepG2.tet cells were serum starved overnight in the presence
or absence of tetracycline (2 ng/ml) and then stimulated with IL-1␤, lysed, and
fractionated.
For in vivo experiments, 6- to 10-week-old gender-matched wild-type and
Ajuba null mice were injected intraperitoneally with 5 ng/g of body weight IL-1␤.
After various times following injection, mice were sacrificed and lungs were
isolated, rinsed with cold phosphate-buffered saline, and frozen immediately on
dry ice. Fractionation of lung was performed by adding 0.5 ml of hypotonic buffer
per 0.1 g of frozen lung tissue; tissue was homogenized and NP-40 was then
added to a 0.5% final concentration, and tissue was kept on ice for 5 min with
vortexing every minute. The sample was spun at 5,000 rpm for 10 min and the
pellets were washed with hypotonic buffer and then extracted with 200 l of
hypertonic buffer to obtain the nuclear extract. The remaining supernatant was
centrifuged at 12,000 rpm for 10 min to obtain the cytosolic extract. The final
concentration of NaCl in each sample was made 120 mM for further analysis.
Total RNA was prepared from lung using Trizol reagent (Invitrogen) following
the manufacturer’s instructions.
Semiquantitative RT-PCR. Reverse transcription (RT) was performed using
the SuperScript III first-strand synthesis system (Invitrogen); 2 g of total RNA
was used for each reaction. Reverse transcribed products (1 l) were used in
PCRs. GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used as internal control. The following PCR primers were used: MIP-2 (CXCL2) forward,
5⬘-CAGTGAGCTGCGCTGTCCAATG; reverse, 5⬘-CAGTTAGCCTTGCCTT
TGTTCAG; GAPDH forward, 5⬘-GCCACCCAGAAGACTGTGGAT; reverse,
5⬘-TGGTCCAGGGTTTCTTACTCC.
Immunoprecipitation and Western blots. For immunoprecipitation of endogenous Ajuba, HepG2 cells were harvested, washed with cold phosphate-buffered
saline, and lysed with IP buffer (20 mM HEPES [pH 7.5], 120 mM NaCl, 5 mM
NaF, 1 mM sodium orthovanadate, 0.5 mM EDTA, 1 mM DTT, 5% glycerol,
0.1% NP-40, and protease inhibitor cocktail from Sigma). Extracts were clarified
by centrifugation at 15,000 ⫻ g for 15 min. For each IP, 2.5 mg of cell extract
protein was mixed with 5 g of affinity-purified Ajuba antibody or preimmune
serum on ice for 2 h and then incubated with 25 l of protein A-protein G slurry
(1:1 [vol/vol]) overnight with gentle rotation at 4°C. The immunoprecipitates
were washed five times with IP buffer and boiled in SDS loading buffer. After
SDS-polyacrylamide gel electrophoresis under reducing conditions, products
were transferred to a nitrocellulose membrane and subjected to p62 Western blot
analysis with ECL reagent (Amersham).
NF-B EMSA. Oligonucleotides for NF-B binding sites were labeled at the 5⬘
end with biotin during synthesis. The following oligonucleotides were used: 5⬘
biotin-AAGTTGAGGGGACTTTCCCAGGCT 3⬘ and 5⬘ biotin-AGCCTGG
GAAAGTCCCCTCAACTT 3⬘. Annealed DNA was purified from a 15% polyacrylamide gel. Two micrograms of nuclear extract protein for each sample was
mixed with electrophoretic mobility shift assay (EMSA) binding buffer [10 mM
HEPES (pH 7.5), 1.5 mM MgCl2, 50 mM KCl, 2.5% glycerol, 1 mM DTT, 0.5
mM EDTA, 0.2 g of poly(dI:dC), 0.2 nM purified biotin-labeled NF-B], and
the final volume was adjusted to 20 l and kept at room temperature for 30 min.
The mixture was subjected to 6% Tris-borate-EDTA–polyacrylamide gel electrophoresis. The NF-B complex signal was detected using HRP-coupled
streptavidin as instructed by the manufacturer (Pierce).
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that is yet to be determined (19). Finally, Zyxin and Ajuba have
been implicated as contributing to mitotic cell cycle regulation.
Zyxin was found to associate with the tumor suppressor hwarts/LATS1 (16), while Ajuba interacts with and activates the
mitotic kinase Aurora A (15).
To further understand Ajuba’s role in environmental signal
transduction, we performed a yeast two-hybrid screen with the
LIM region of Ajuba. We identified the atypical protein kinase
C (aPKC) scaffold protein, p62, as an Ajuba binding partner. A
prominent function of p62 is the regulation of NF-B activation in response to interleukin-1 (IL-1), nerve growth factor
(NGF), tumor necrosis factor (TNF), and receptor activator of
NF-B ligand (RANKL) signaling through the formation of an
aPKC/p62/TRAF6 multiprotein signaling complex. We present
evidence indicating that Ajuba is a new cytosolic component of
the IL-1 signaling pathway modulating IL-1-induced NF-B
activation by influencing the assembly and activity of the
aPKC/p62/TRAF6 multiprotein signaling complex.
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FIG. 1. The LIM protein Ajuba associates with the aPKC-interacting protein p62. (A) Stick figure representation of Ajuba. The gray boxes
represent the three LIM domains present in the C-terminal LIM region. The PreLIM region is N terminal. (B) Ajuba and p62 associate in human
HepG2 cells. Cell extracts were immunoprecipitated with preimmune serum (PI, lane 1) or Ajuba antiserum (lane 2). Bound products were
Western blotted for the presence of p62. In lane 3, 0.5% of the amount of cell extract used for immunoprecipitation (input) was run. (C) Ajuba
and p62 colocalize in cells. Fibroblasts were transfected with Flag-tagged p62 alone (panel i), myc-tagged Ajuba alone (panel ii), or both p62-Flag
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RESULTS
The LIM protein Ajuba associates with the aPKC-interacting protein p62. To further understand the potential function(s) of Ajuba in intracellular signaling pathways, we sought
to identify cellular proteins interacting with Ajuba. Towards
this aim, a yeast two-hybrid protein-protein interaction screen
was performed using the C-terminal LIM region (three LIM
domains) of human Ajuba as bait (Fig. 1A). Since Ajuba is
abundantly expressed in skin, a human keratinocyte library was
screened. Two of the five true positive interacting clones coded
for p62, an aPKC-interacting protein (35, 40), or phosphotyrosine-independent p56lck SH2-interacting protein (18). Both
clones contained a partial cDNA encoding the N-terminal portion (amino acids [aa] 1 to 266 and aa 1 to 333) of p62.
To determine whether Ajuba and p62 interact with one
another in cells expressing endogenous levels of each protein,
Ajuba was immunoprecipitated from the human hepatocyte
cell line, HepG2, and bound p62 was detected by Western
blotting. A significant proportion of cellular p62 was present in
Ajuba immunoprecipitates, while preimmune serum did not immunoprecipitate p62 protein (Fig. 1B). Next, we asked whether
Ajuba and p62 colocalized in cells. To do so, MC3T3 cells were
transfected with myc-tagged Ajuba and Flag-tagged p62 plasmids, either alone or together, and indirect immunofluorescence was performed on fixed cells. Consistent with previous
reports, when expressed alone, p62 localized to punctate, vesicular structures (endosomes) (Fig. 1Ci, arrows) (40), while
Ajuba was diffusely distributed throughout the cytoplasm and
present at focal adhesion sites (Fig. 1Cii, arrowheads) (34).
When p62 and Ajuba were coexpressed, Ajuba colocalized with
p62 at vesicular structures (Fig. 1Ciii, iv, and v, arrows), and
p62 colocalized with Ajuba at some, but not all, focal adhesion
sites (Fig. 1Ciii, iv, and v, arrowheads). Together, these two
results indicated that Ajuba interacted with p62 in cells.
In mammals there are five related Ajuba family members:
Ajuba, LIMD1, Zyxin, LPP, and Trip6. The homology between
these proteins is in the three C-terminal LIM domains. Phylogenetic analysis, protein sequence analysis, and overall protein

organization suggest that Ajuba and LIMD1 may form a subfamily, while Zyxin, LPP, and Trip6 are more closely related to
one another than Ajuba or LIMD1. To determine whether
there was specificity among Ajuba/Zyxin family proteins for
interacting with p62, HEK293 cells were cotransfected with
myc-tagged LIM proteins and Flag-tagged p62, p62 was immunoprecipitated (anti-Flag), and then bound products were
Western blotted for the presence of LIM protein (anti-Myc).
Only Ajuba and related LIMD1 associated with p62 (Fig. 1D).
Zyxin and LPP did not associate with p62 (Fig. 1D). Mapping
studies were then performed to determine the region of Ajuba
directing its association with p62. Full-length Ajuba and the
LIM region of Ajuba associated with p62, while the PreLIM
region of Ajuba did not (Fig. 1E). Similar results were obtained from LIMD1 mapping studies (data not shown). These
results indicated that there was specificity in the LIM protein
family members interacting with p62 and that the LIM region
of Ajuba directed its interaction with p62.
Ajuba is required for efficient IL-1- and TNF-induced activation of NF-B by affecting IKK activation. p62 associates
with the atypical PKCs ( and ) (35, 40), receptor-interacting
protein (RIP) (42), and TRAF6 (41) and as such is thought to
function as a scaffolding protein influencing IL-1, TNF, NGF,
and RANKL signaling to activate NF-B (8, 41, 42, 45). Since
the LIM protein Ajuba interacted with p62, we asked whether
Ajuba influenced NF-B activation in response to IL-1 or TNF
stimulation. To test this possibility, primary cells from Ajuba
null mice and in vivo stimulation of Ajuba null mice were both
evaluated.
First, Ajuba⫺/⫺ primary MEFs were compared to wild-type
(wt) (Ajuba⫹/⫹), littermate-matched cells (loss of Ajuba model). MEFs were stimulated with IL-1␤ (two different littermatched sets) or TNF-␣. NF-B activation was determined by
EMSAs of nuclear extracts. In two different litter-matched sets
of MEFs, NF-B activation was reduced in Ajuba null MEFs in
response to both IL-1 and TNF stimulation (Fig. 2A). The
observed EMSA was specific for NF-B, as the addition of
antibodies to the nuclear p50 subunit of NF-B to the EMSA
reaction completely shifted the band, while control antibodies
did not (see Fig. 5B). IL-1-induced IB phosphorylation, which
was required for the release of cytoplasmic NF-B complexes
and subsequent translocation into the nucleus, was also reduced in Ajuba⫺/⫺ MEFs compared to wt controls (Fig. 2B,
upper panel), suggesting that Ajuba contributed to the cytosolic activation of NF-B. Consistent with decreased I〉 phosphorylation, I〉␣ protein was more stable in Ajuba null cells
(Fig. 2B, lower panel). Finally, the transcription of I〉␣, an
NF-B-regulated gene, was decreased in Ajuba null cells subsequent to IL-1 stimulation (Fig. 2B, lower panel, 60-min time
point).

and myc-Ajuba (panels iii to v) and immunostained for p62 (anti-Flag, red, panels i and iii) or Ajuba (anti-myc, green, panels ii and iv). Panel v
is a merged image of panels iii and iv. Arrows identify vesicular, endosomal structures. Arrowheads identify focal adhesion sites. (D) Ajuba and
LIMD1 but not Zyxin or LPP associate with p62. HEK293 cells were transfected with p62 (Flag-tagged) and myc-tagged LIM proteins, as indicated.
p62 was immunoprecipitated (anti-Flag), and bound products were Western blotted for the presence of LIM protein (anti-myc, upper panels) and
p62 (anti-Flag, lower panels). For each set, input controls were run (5% of amount used for immunoprecipitation). (E) Mapping of the region of
Ajuba that interacts with p62. HEK293 cells were transfected with myc-tagged p62 and Flag-tagged isoforms of Ajuba, as indicated. Ajuba was
immunoprecipitated (anti-Flag), and bound products were Western blotted for the presence of p62 (anti-myc, left upper panel) and Ajuba isoforms
(anti-Flag, left lower panel). Five percent of the cell extract used for immunoprecipitation was run as an input control (right panels).
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IKK kinase assay. Lung cytosolic extracts containing 500 g of total protein
were incubated with 5 l of IKK␥ antibody for 2 h, followed by overnight
incubation with 25 l of protein A-protein G (1:1). Beads were washed with IP
buffer, and then the IKK␥ kinase assay was performed as described by Lallena et
al. (23), using purified glutathione S-transferase (GST)–IB␣(1-54) as an exogenous substrate.
PKC kinase assay. Purified PKC was mixed with baculovirus-produced and
purified Ajuba, PreLIM peptide, and LIM peptide on ice for 20 min in kinase
buffer (sonicated 20 mM MOPS [morpholinepropanesulfonic acid], pH 7.2, 25
mM ␤-glycerolphosphate, 1 mM sodium orthovanadate, 1 mM DTT, 1 mM
CaCl2, 0.1 mg/ml phosphatidylserine). ATP (50 M and containing 250 Ci/ml
[␥-32P]ATP) and MgCl2 (1.5 mM) were added. Kinase reactions were started by
mixing 40 l of kinase buffer with enzyme mixture and incubated at 30°C for
10 min.
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When Ajuba was stably reintroduced into Ajuba⫺/⫺ MEFs,
NF-B activation, in response to IL-1␤ and TNF-␣, returned
to levels observed in wt MEFs or greater (Fig. 2C), indicating
that the absence of Ajuba was directly related to decreased
NF-B activation. Furthermore, the level of exogenous Ajuba

protein present in Ajuba-rescued Ajuba⫺/⫺ MEFs was greater
than that present in wt MEFs (fivefold) (Fig. 2C, lower panel)
and NF-B activity in Ajuba-rescued Ajuba⫺/⫺ MEFs was
greater than that observed in wt MEFs; this suggested that
when Ajuba was overexpressed in primary MEFs, activation of
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FIG. 2. Ajuba is required for efficient activation of NF-B by IL-1 and TNF. (A) Two sets of litter-matched Ajuba⫺/⫺ and control wt MEFs
were stimulated with IL-1␤ (10 ng/ml) or TNF-␣ (10 ng/ml) for the indicated times. Nuclei were isolated, and EMSA with NF-B-specific
oligonucleotides was performed, as described in the text. Equal amounts of nuclear extracts were used in each lane. The percent NF-B activity
in Ajuba null cells compared to control wt cells is indicated under each lane. (B) Ajuba⫺/⫺ and control wt MEFs were treated as in panel A, and
cytosolic fractions from the same experimental cells were Western blotted for phospho-I〉 (upper panel) and total I〉␣ protein (lower panel).
The percent NF-B activity in Ajuba null cells compared to control wt cells is indicated under each lane. (C) Ajuba⫺/⫺ (left lane) and Ajuba null
MEFs stably expressing exogenous Ajuba (right lane) were treated as described for panel A, and nuclear EMSA for NF-B activity was performed.
The percent NF-B activity in Ajuba-rescued cells compared to Ajuba null cells is indicated under each lane. The lower panel is an anti-Ajuba
Western blot comparing the level of Ajuba protein in wt (⫹/⫹), Ajuba null (⫺/⫺), and Flag-tagged Ajuba-rescued Ajuba null MEFs (⫺/⫺, ⫹A).
Equal amounts of protein were loaded in each lane. (D) Zyxin⫺/⫺ and control wt MEFs were stimulated with IL-1␤ (10 ng/ml) for the indicated
times. Nuclei were isolated, and EMSA with NF-B-specific oligonucleotides was performed, as in panel A. Equal amounts of nuclear extracts were
used in each lane. The percent NF-B activity in Zyxin null cells compared to control wt cells is indicated under each lane. (E) Ajuba⫺/⫺ and
control wt MEFs were treated as in panel A, and the same cytosolic fractions were Western blotted for phospho-JNK, total JNK-1, phospho-ERK,
total ERK1, phospho-p38, and total p38 protein. Equal amounts of protein were loaded in each lane.
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NF-B by IL-1 was enhanced and was consistent with the
decrease in NF-B activation observed in Ajuba null MEFs
(Fig. 2A).
Since the Ajuba-related LIM protein Zyxin did not interact
with p62 (Fig. 1D), we asked whether IL-1 signaling was influenced by loss of Zyxin. IL-1 stimulation of Zyxin⫺/⫺ MEFs
was compared to wt (Zyxin⫹/⫹) control MEFs. In contrast to
Ajuba⫺/⫺ MEFs, we observed no diminution of NF-B activation (Fig. 2D) or significant alteration in any of the mitogenactivated protein kinase (MAPK) activation profiles in Zyxin⫺/⫺
MEFs in response to IL-1 (see Fig. S1B in the supplemental
material), suggesting that the interaction between Ajuba and
p62 was important for Ajuba’s effect upon NF-B activation
following IL-1 stimulation.
IL-1 signals also activate the MAPKs ERK, JNK, and p38,
yet precisely how these kinases are activated is less clear (7).
We determined whether the loss of Ajuba influenced IL-1induced activation of JNK, ERK, and p38 by analyzing
Ajuba⫺/⫺ MEFs versus control wt MEFs. Following stimulation with IL-1, Ajuba⫺/⫺ MEFs exhibited a slight reduction in
p38 activation and a persistence of JNK activation relative to
Ajuba⫹/⫹ MEFs (Fig. 2C). There were no significant changes
in ERK activation between wt and Ajuba null MEFs, however
(Fig. 2E).
The levels of p62, TRAF6, PKC, and other Ajuba family
LIM proteins were determined in IL-1-stimulated Ajuba⫺/⫺
and Ajuba⫹/⫹ MEFs (see Fig. S1A in the supplemental material). In the absence of Ajuba, the level of related LIM protein
family members was not altered. IL-1 stimulation did not alter
the protein level of any of the adapter proteins (p62 and
TRAF6) or kinase (PKC) analyzed. A slight increase in Ajuba

protein level was apparent after 60 min of IL-1 stimulation of
wt MEFs.
These analyses in primary MEFs revealed that Ajuba was
required for IL-1 and TNF signaling to efficiently activate
NF-B. This effect was specific to the Ajuba LIM protein, as
loss of the related LIM protein Zyxin, which does not interact
with p62, did not affect NF-B activation following IL-1 stimulation, suggesting that Ajuba’s interaction with p62 was important for its regulation of NF-B activity.
The level of Ajuba protein in MEFs is relatively low compared to other tissues. Epithelial cells contain much higher
levels of Ajuba (27). PKC, which also interacts with p62, was
also shown to only modestly affect NF-B activity in MEFs
(low level of PKC); however, when the lung (high level of
PKC) from PKC null mice was examined following IL-1
stimulation in vivo, a much greater inhibition of NF-B was
observed (24). Since Ajuba levels in the lung are much higher
than in MEFs (26), NF-B activation in the lungs of Ajuba null
mice was determined following intraperitoneal injection of
IL-1. The extent of NF-B inhibition in the lungs of Ajuba null
mice was found to be much greater than observed in MEFs
(Fig. 3A). Moreover, as observed in PKC knockout mice,
nuclear transport of the p65 subunit of NF-B was also inhibited in Ajuba null lungs (Fig. 3A) (24). In addition, transcription of the NF-B-regulated genes CXCL2 or MIP-2 (44) was
decreased in Ajuba null lung in response to IL-1 (Fig. 3B).
PKC modulates NF-B activity through an effect upon IKK
activity in lung (24); therefore, we asked whether, in the absence of Ajuba, lung IKK activity was also inhibited following
IL-1 stimulation. IKK␥ was immunoprecipitated from IL-1stimulated lung extracts, and in vitro kinase assays using GST-
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FIG. 3. Ajuba is required for IL-1-induced NF-B activation in vivo through activation of IKK activity. (A) Ajuba⫺/⫺ and control wt mice were
injected with IL-1␤ for the indicated times. Nuclear extracts from the lungs of these mice were analyzed by NF-B EMSA assays (upper panel),
nuclear p65 subunit of NF-B Western blotting (middle panel), and nucleophosmin Western blotting of nuclear extracts as a loading control (lower
panel). (B) Semiquantitative RT-PCR analysis of lungs from IL-1␤-injected mice for the level of the NF-B-responsive gene CXCL2 (MIP-2) (44)
(upper panel). Loading control is GAPDH (lower panel). (C) IKK in vitro kinase assay of cytosolic extracts from the lungs of the mice described
for panel A. GST-I〉␣(1-54) was used as exogenous substrate.
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I〉␣ as substrate were performed. IKK activity was inhibited
in Ajuba null lungs, compared to wt controls, following IL-1
stimulation (Fig. 3C). Thus, when tissues (e.g., lung) expressing
high levels of Ajuba were analyzed, a much greater inhibition
of IL-1-stimulated NF-B activity was observed. In lung, it
appeared that Ajuba, like PKC, affected NF-B activation by
regulating IKK activity.
A unique domain in p62, not overlapping with aPKC or
TRAF6 binding sites, directs its interaction with Ajuba. p62
interacts with signaling proteins important for the activation of
NF-B by IL-1 (reviewed in reference 10). Specifically, the
aPKCs interact with the aPKC-interacting domain (AID) near
the N terminus (35), and TRAF6 interacts with a domain
(T6) present at aa 225 to 251 of p62 (41). In addition, the TNF
signaling intermediate RIP associates with p62 at the zinc
finger domain (ZZ) (42). To determine the region of p62
mediating its interaction with Ajuba, a series of Flag-tagged
p62 truncation and deletion mutants (Fig. 4D) was cotransfected with myc-tagged Ajuba into HEK293 cells. p62 mutants
were immunoprecipitated using anti-Flag antibody and bound
products Western blotted for the presence of Ajuba (antimyc). Analysis of a panel of p62 truncation mutants indicated
that the N-terminal 1 to 220 amino acids were critical for the
interaction with Ajuba (Fig. 4A). Further deletion of aa 170 to
220 resulted in the loss of Ajuba binding to p62 (Fig. 4A, lane
6), indicating that this region of p62 was important to mediate
the association between p62 and Ajuba.
To confirm that this region was indeed required to direct
p62’s association with Ajuba, a panel of p62 deletion mutants
was tested. Deletion of aa 170 to 220, in the context of fulllength p62, resulted in the loss of association with Ajuba (Fig.

4B, lane 3), while deletion of AID (aa 66 to 82), the ZZ domain (RIP-interacting domain, aa 128 to 163), and the TRAF6
(T6) binding domain (aa 225 to 255) had no effect upon p62’s
association with Ajuba (Fig. 4C, lanes 3, 4, and 5, respectively).
We have named the domain between aa 170 and 220 of p62
a new LIM protein-binding region (LB). Importantly, the LB
domain of p62 did not overlap with the binding sites for other
IL-1 or TNF signaling intermediates, such as aPKC, TRAF6,
and RIP.
Ajuba levels affected the amount of TRAF6 present in the
p62/PKC signaling complex. To determine biochemically
whether Ajuba regulates the p62 signaling complex and how,
we turned to an Ajuba inducible cell line. We generated
HepG2 cell lines containing a tetracycline-regulated, Flagtagged Ajuba plasmid. HepG2 cells were used, as they are
human and available antibodies to p62 only immunoprecipitate
human p62, precluding a similar analysis in mouse cells.
HepG2 cells express endogenous Ajuba, and this level was not
affected by IL-1 stimulation (data not shown). Due to leakiness
of the promoter, a small amount of Flag-Ajuba was expressed
in the absence of tetracycline, but following the addition of
increasing amounts of tetracycline (2 to 250 ng/ml) FlagAjuba expression progressively increased (Fig. 5A). To ensure that the observed NF-B activity in IL-1-stimulated
HepG2.tetAjuba cells was indeed NF-B, cells were induced
with tetracycline, and EMSA assays were performed in the
presence of antibodies to the p50 subunit of NF-B or control
Ajuba or Flag antibodies. Anti-p50 antibodies completely
shifted the NF-B complex (Fig. 5B), while Ajuba and Flag
antibodies had no effect on the mobility of the NF-B complex
(Fig. 5B). This result also indicated that Ajuba was not present
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FIG. 4. A unique domain in p62, not overlapping with aPKC or TRAF6 binding sites, directs its interaction with Ajuba. HEK293 cells were
cotransfected with myc-tagged Ajuba and Flag-tagged p62. p62 (anti-Flag) was immunoprecipitated, and bound products were Western blotted for
the presence of Ajuba (anti-myc) and p62 (anti-Flag) (left panels). Right panels show input controls. (A) Mapping of the p62 truncation mutants.
(B and C) Mapping of p62 deletion mutants. (D) Stick figure representation of p62 mutants tested and those that associate with Ajuba. AID is
the atypical PKC-interacting domain, ZZ is the zinc finger RIP-interacting domain, LB is the novel LIM protein binding domain, and T6 is the
TRAF6 binding domain.
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in a nuclear complex containing the p50 protein of the NF-B
complex.
TRAF6 is an important adapter protein in IL-1-induced
NF-B activation. TRAF6 null MEFs are defective in NF-B
activation following IL-1 stimulation (25). TRAF6 is thought
to activate NF-B by interacting with transforming growth
factor-activated kinase TAK1 and its regulator TAB-1 to activate IKK (29, 39). TRAF6 forms a complex with p62 and PKC
in an IL-1-dependent manner, and this complex influences
IL-1-induced NF-B activity (41). Since Ajuba interacts with a

unique domain in p62 and Ajuba affects IL-1-induced NF-B
activation, Ajuba may influence IL-1 signaling by affecting the
assembly of the p62/PKC/TRAF6 multiprotein signaling complex. To test this hypothesis, we induced overexpression of
Ajuba in HepG2 cells and then treated them with IL-1 for
increasing periods of time (0 to 30 min). Exogenous Ajuba
(Fig. 5C) or endogenous p62 (Fig. 5D) was immunoprecipitated, and bound products were Western blotted for endogenous TRAF6, PKC, and p62. In the absence of IL-1 Ajuba,
p62, and PKC but not TRAF6 were present in a multiprotein
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FIG. 5. Ajuba recruits TRAF6 into the p62/PKC signaling complex. (A) HepG2 cells containing tet-regulated Ajuba (Flag-tagged) were
stimulated with differing concentrations of tetracycline, and Ajuba (anti-Flag) Western blotting was performed. (B) NF-B supershift assay. HepG2
cells containing tet-regulated Ajuba (Flag-tagged) were induced with tetracycline (2 ng/ml) and then stimulated with IL-1␤ (10 ng/ml). Nuclei were
isolated, and NF-B EMSA was performed in the absence (lane 2) or presence of antibodies to the p50 subunit of NF-B (lane 3), Flag (lane 4),
or Ajuba (lane 5). NS indicates nonspecific bands. (C and D) HepG2 cells containing tet-regulated Ajuba (Flag-tagged) were induced with
tetracycline (2 ng/ml) and then stimulated with IL-1␤ (10 ng/ml) for the indicated times. Ajuba (anti-Flag) (C) or endogenous p62 (D) were
immunoprecipitated, and bound products were Western blotted for the presence of endogenous p62, TRAF6, PKC, and p38 as a negative control.
Right panels show input controls. (E) HEK293 cells were cotransfected with fixed amounts of TRAF6 (myc-tagged), either p62 (Flag-tagged) (left
panels) or p62.⌬225-255 (right panels), and increasing amounts of HA-tagged Ajuba. p62 was immunoprecipitated (anti-Flag), and bound products
were Western blotted for the presence of TRAF6 (anti-myc), Ajuba (anti-HA), and p62 (anti-Flag) (left panels). Right panels show input controls.
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complex coimmunoprecipitating with Ajuba (Fig. 5C, lane 2).
Following IL-1 addition, the amount of p62 present in Ajuba
immunoprecipitates increased slightly, while the levels of
PKC did not appreciably change (Fig. 5C, lanes 3 to 5).
Interestingly, however, following IL-1 stimulation TRAF6 was
recruited into the Ajuba/p62/PKC complex (Fig. 5C, lanes 3
to 5). Similar results were observed when endogenous p62 was
immunoprecipitated, and bound products were Western blotted for Ajuba (Flag), endogenous TRAF6, and endogenous
PKC (Fig. 5D). These results suggested that Ajuba could
increase the recruitment of TRAF6 to a p62/PKC complex
following IL-1 stimulation.
To further test this hypothesis, HEK293 cells were transfected with fixed amounts of Flag-tagged p62 and myc-tagged
TRAF6 and increasing amounts of HA-tagged Ajuba. p62 was
immunoprecipitated, and bound products were Western blotted for TRAF6 and Ajuba. Overexpressed p62 and TRAF6
associated in HEK293 cells in the absence of exogenous Ajuba.
Following transfection with increasing amounts of Ajuba, substantially more TRAF6 was now present in the p62 immunoprecipitates (Fig. 5E, left panel, lanes 3 and 4), suggesting that
Ajuba levels influence the amount of TRAF6 recruited to p62.
To address the molecular mechanism of this process, we
transfected cells with fixed amounts of a mutant form of p62
that no longer binds TRAF6 (p62.⌬225-255) (Fig. 4A), TRAF6,
and increasing amounts of Ajuba. p62 was immunoprecipitated, and bound products were Western blotted for TRAF6

and Ajuba. In the absence of exogenous Ajuba, very little
TRAF6 associated with p62.⌬225-255, as anticipated (Fig.
5E, right panel, lane 2); however, following transfection with
increasing amounts of Ajuba, TRAF6 was still recruited to
p62.⌬225-255 (Fig. 5E, right panel, lanes 3 and 4), albeit at
levels less than detected in cells transfected with wild-type p62
(Fig. 5E, left panel). Therefore, although a p62 protein lacking
its TRAF6 binding domain does not efficiently interact with
TRAF6, Ajuba can promote the recruitment of TRAF6 to p62,
suggesting that Ajuba may itself bind TRAF6, thereby further
increasing TRAF6 recruitment into the p62/PKC signaling
complex.
Ajuba interacts with TRAF6. To test whether Ajuba does
interact with TRAF6, HEK293 cells were transfected with
Ajuba and various truncation mutants of TRAF6 (Fig. 6C) or
TRAF2 as a negative control (not part of the IL-1 signaling
pathway and does not interact with p62 [41]). TRAF6 associated with Ajuba in cells (Fig. 6A, lane 2), while TRAF2 did not
(data not shown). TRAF6 mapping studies demonstrated that
its interaction with Ajuba was largely directed by the TRAF-N
region (aa 270 to 352) within the C-terminal TRAF domain
(Fig. 6A, lane 6). Deletion of the TRAF-C region of the TRAF
domain also had a small effect on the amount of Ajuba bound
to TRAF6 (Fig. 6A, lane 5). Ajuba mapping studies demonstrated that the LIM region of Ajuba directed its association
with TRAF6, and the PreLIM region did not interact with
TRAF6 (Fig. 6B). Therefore, in addition to interacting with

Downloaded from http://mcb.asm.org/ on January 6, 2014 by Washington University in St. Louis

FIG. 6. Ajuba interacts with TRAF6. (A) Mapping of the TRAF6 domains required for an interaction with Ajuba. HEK293 cells were
cotransfected with myc-tagged Ajuba and Flag-tagged TRAF6 isoforms. TRAF6 (anti-Flag) was immunoprecipitated, and bound products were
Western blotted for the presence of Ajuba (anti-myc) and TRAF6 (anti-Flag) (left panels). Right panels show input controls. (B) Mapping of the
Ajuba regions required for an interaction with TRAF6. HEK293 cells were cotransfected with Flag-tagged Ajuba isoforms and myc-tagged TRAF6.
Ajuba isoforms (anti-Flag) were immunoprecipitated, and bound products were Western blotted for the presence of TRAF6 (anti-myc) and Ajuba
(anti-Flag) (left panels). Right panels show input controls. (C) Stick figure representation of TRAF6 mutants and their association with Ajuba. The
light gray box is the RING finger domain, the black box is the five zinc fingers, the dark gray box is the N-terminal region of the TRAF domain,
and the hatched box is the C-terminal region of the TRAF domain.
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p62, Ajuba also interacts with TRAF6. Likewise, TRAF6 interacts with p62 and Ajuba.
Ajuba interacts with PKC, is a substrate for PKC, and
activates PKC activity. In addition to TRAF6, PKC also
activates IKK, leading to activation of NF-B following IL-1
stimulation (14, 24). TRAF6, through its interaction with p62,
may also influence PKC activity (41). Since Ajuba interacts
with p62 and TRAF6, increasing the recruitment of TRAF6 to
p62, and affects IL-1-induced NF-B activity, it begs the question: does Ajuba influence IL-1-induced NF-B activity by
interacting with PKC or affecting its enzyme activity?

When Ajuba was immunoprecipitated from HepG2 cells,
p62 and PKC were present in the immunoprecipitate (Fig.
5C). PKC could be present in this Ajuba protein complex by
virtue of its interaction with p62, through an association with
Ajuba independent of p62, or both. Therefore, to determine
whether PKC interacted with Ajuba, HEK293 cells were cotransfected with various Flag-tagged truncation mutants of
PKC (Fig. 7C) and myc-tagged Ajuba. PKC was immunoprecipitated and bound products Western blotted for the presence of Ajuba. PKC did indeed associate with Ajuba, and this
interaction mapped to the N-terminal 1 to 244 aa of PKC
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FIG. 7. Ajuba interacts with PKC, activates PKC, and is a substrate of PKC. (A) Mapping of the PKC region required to interact with
Ajuba. HEK293 cells were cotransfected with myc-tagged Ajuba and Flag-tagged PKC mutants. PKC isoforms were immunoprecipitated
(anti-Flag), and bound products were Western blotted for the presence of Ajuba (anti-myc) (left panels). Right panels show input controls.
(B) Mapping of the Ajuba region required to interact with PKC, as described for panel A. (C) Stick figure representation of PKC mutants and
their interaction with Ajuba. (D) Coomassie-stained gel of baculovirus-produced and purified Ajuba, PreLIM peptide of Ajuba, and LIM peptide
of Ajuba. Molecular weight markers in thousands are on the left. (E) In vitro PKC kinase assays. A fixed amount of purified PKC (20 ng) was
mixed with increasing amounts of Ajuba protein (upper panel) or PreLIM and LIM peptides (lower panel). Arrows identify the location of PKC
and Ajuba peptides. (F) Purified PKC (20 ng) was mixed with PreLIM peptide (400 ng). Increasing amounts of Ajuba LIM peptide were added,
and an in vitro kinase reaction was performed. In this assay, more nonradioactive ATP was present than in panel E. The arrow identifies a
phosphorylated PreLIM peptide. The increase (n-fold) in PreLIM phosphorylation relative to that observed in the absence of LIM peptide (set
at 1) is shown below each lane.
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DISCUSSION
Herein we demonstrate that the LIM protein Ajuba is a new
component of the proinflammatory cytokines IL-1 and TNF
signal transduction cascades regulating NF-B activation.
IL-1 can activate NF-B by interrelated signaling pathways
(reviewed in references 7 and 10). First, IL-1 interacts with a
specific cell surface receptor (IL-1R) on target cells. Receptor
activation leads to the recruitment of the myeloid differentiation factor (MyD88) to the receptor complex. MyD88 serves to
further recruit members of the IL-1R kinase family (IRAK) to
the receptor complex. IRAK plays a critical role in the activation of NF-B through its interaction with TRAF6. In response
to IL-1, TRAF-6 becomes ubiquitinated, oligomerizes, and
interacts with TAB-2, the transforming growth factor-activated
kinase 1 (TAK1), and TAB-1. Activated TAK1 can then activate the I〉 kinase complex (IKK), leading to phosphorylation
of I〉 and its subsequent degradation with release of NF-B
proteins and their translocation into the nucleus, where inflammatory, apoptotic, or antiapoptotic pathways are regulated,
depending upon cell type (3, 4).
Alternatively, IL-1 can activate NF-B through a cytosolic
pathway involving aPKC (13, 38), p62 (41), and TRAF6 (41).
p62 has been proposed to function as a scaffold protein, in that
it interacts with both PKC and TRAF6 in an IL-1-dependent
manner. Dominant negative aPKC blocks IL-1-induced and
TRAF6-induced NF-B activation (41), suggesting that TRAF6,
when bound to p62, may activate aPKC. Furthermore, the aPKC/

p62/TRAF6 complex appears to function downstream of IRAK
(41). Cells and organs from mice deficient in p62 (41), TRAF6
(25, 28), or PKC (24) all exhibit defective NF-B activation in
response to proinflammatory cytokines of the IL-1 family.
Primary MEFs from Ajuba null mice and the lungs from
Ajuba null mice injected with IL-1 have diminished NF-B
activation following IL-1 and TNF stimulation. This defect in
NF-B activation is biologically relevant, as Ajuba null MEFs
are more sensitive to TNF-induced apoptosis (data not shown),
and reintroduction of Ajuba into Ajuba null MEFs rescues the
IL-1- and TNF-induced NF-B signaling defect and prevents
TNF-induced cell death. Likewise, overexpression of Ajuba in
primary MEFs increased NF-B activity following IL-1 stimulation.
We propose that Ajuba influences IL-1-induced NF-〉 activation by affecting the assembly of the PKC/p62/TRAF6
multiprotein complex in cells and thus IKK activity. Using
purified proteins in vitro, we also found that Ajuba could be a
PKC substrate and enhance PKC activity. The aPKC-interacting protein p62 was identified as interacting with Ajuba in a
two-hybrid screen, and endogenous p62 coimmunoprecipitates
and colocalizes with endogenous Ajuba in cells. Within the
Ajuba-related LIM protein family, there was specificity in interacting with p62. Importantly, p62-noninteracting Zyxin null
MEFs have no defect in IL-1-induced NF-B activity, suggesting that Ajuba’s interaction with p62 was crucial for its regulation of NF-B activity.
In addition to interacting with p62, Ajuba also interacted
with TRAF6. The interaction with TRAF6 was also specific, as
Ajuba did not interact with related TRAF2. Mapping studies
identified the TRAF domain of TRAF6 as mediating its interaction with Ajuba. Within the TRAF family, the TRAF domain in TRAF6 is most divergent (1). Other proteins interacting with this domain are p62 (41) and ECSIT (22), and each,
like Ajuba, is specific for TRAF6. The TRAF domain is responsible for oligomerization of TRAF6, which is thought to
be critical for signaling by the N-terminal region (3). Progressive overexpression of Ajuba results in increased recruitment
of TRAF6 to p62 and enhanced NF-B activity. So it is possible that Ajuba and p62 serve to “activate” TRAF6, bringing
its effector domain into close proximity to PKC bound to p62
or its other downstream kinase, TAK1 (Fig. 8).
Mapping studies identified a unique domain (LB domain) in
p62 that directs its association with Ajuba. Importantly, the LB
domain does not overlap with the aPKC, RIP, or TRAF6
binding domains previously identified in p62 (41, 42). Interestingly, the LB domain of p62 lies just N-terminal to the TRAF6
binding domain. Taken together, these observations suggest
the following possibilities for how Ajuba could influence the
recruitment of TRAF6 to p62: (i) following Ajuba binding to
p62, TRAF6 could be recruited to p62 through an interaction
with Ajuba or p62 (i.e., independent binding sites); (ii) a preformed Ajuba-TRAF6 protein complex could be recruited to
p62; (iii) Ajuba could stabilize the association of TRAF6 with
p62; (iv) Ajuba could also influence the activation (i.e., oligomerization and ubiquitination) of TRAF6 bound to p62 (6,
43); or (v) some combination of the above mechanisms. Future
biochemical studies with purified protein components and genetic studies of mutant proteins expressed in cells from knockout mice should begin to address these possibilities.
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(Fig. 7A). Ajuba did not interact with the C-terminal kinase
domain of PKC (Fig. 7A). Ajuba mapping studies demonstrated that the LIM region of Ajuba directed its association
with PKC and that the PreLIM region did not interact (Fig.
7B).
Ajuba is a phosphoprotein (12, 15). Therefore, we next
asked whether Ajuba could be a substrate for PKC and
whether Ajuba affected PKC activity. Full-length Ajuba, the
PreLIM region of Ajuba, and the LIM region of Ajuba were
expressed in baculovirus and purified (Fig. 7D). A fixed
amount of pure PKC was mixed with increasing amounts of
purified Ajuba protein, and kinase reaction in the presence of
[32P]ATP was performed. Both full-length Ajuba and the PreLIM region were phosphorylated by PKC, while the LIM
region was not (Fig. 7E). In addition, autophosphorylation of
PKC was enhanced by the presence of full-length Ajuba and
the LIM region of Ajuba (both interact with PKC), and the
extent of PKC autophosphorylation increased with increasing
amounts of added Ajuba or LIM region (Fig. 7E). The LIM
region alone appeared to activate PKC to the greatest extent.
Next, we mixed PKC and Ajuba PreLIM peptide (“substrate”) and then added increasing amounts of LIM region
peptide (“activator”) to the reaction. In the presence of increasing amounts of LIM region, more PreLIM peptide was
phosphorylated (Fig. 7F). The intensity of phosphorylation was
less than that observed in Fig. 7E because larger amounts of
nonradioactive ATP, in excess of [32P]ATP, were added to the
kinase reaction. These in vitro data suggested that Ajuba (specifically the PreLIM region) could be a substrate of PKC and
that binding of Ajuba (particularly the LIM region) activated
PKC enzyme activity.
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We also found that Ajuba could interact with PKC independently of p62. In vitro, Ajuba activated PKC enzyme activity, and Ajuba could be a PKC substrate. Interestingly, the
LIM region of Ajuba activates PKC but is not phosphorylated, whereas the PreLIM is readily phosphorylated by PKC
but does not significantly activate PKC activity. That components of Ajuba are more efficient as activator and substrate
than the full-length protein suggests the possibility that Ajuba
may exist in an inhibited conformation, possibly with the PreLIM region folded back on the LIM regions, as has been
suggested for Vinculin, WASP, and another LIM protein,
Tes (9, 11), or may be inaccessible due to an interaction with
another cellular protein. Phosphorylation of the PreLIM region of Ajuba could then possibly open up the structure or
release it from a cellular complex, now allowing for the LIM
region to interact with p62, TRAF6, and PKC. An interaction
with PKC could further activate PKC activity, thereby influencing NF-B activation.
In addition to regulating NF-B activity, IL-1 signals also
modulate the activity of the MAPKs, particularly JNK and p38.
While Ajuba appeared to have a mild effect upon p38 activity,
there was sustained activation of JNK in Ajuba null MEFs.
JNK can be activated by TRAF6-activated TAK1, which can
also activate NF-B (3). Whether TRAF6-regulated TAK1
activity is altered in Ajuba null cells is unknown. Alternatively,
sustained JNK activity in Ajuba null cells may simply result
from the inhibition of NF-B (37).
When one compares the activation of NF-B by the IL-1
family of proinflammatory cytokines in primary cells from
knockout mice, Ajuba’s action overlaps with that observed for
TRAF6⫺/⫺ (21, 25, 28) and PKC⫺/⫺ (24) mice. p62 knockout
mice have not been fully analyzed (8). In vivo, TRAF6⫺/⫺ and
p62⫺/⫺ mice both have defects in bone metabolism through
effects upon IL-1, TNF, and RANKL signaling during oste-
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oclast differentiation. Ajuba is present at low levels in BMDM
and doesn’t change during RANKL differentiation into osteoclasts (Y. Feng and G. Longmore, unpublished). Thus, we
saw no change in LPS-induced NF-B activity in Ajuba⫺/⫺
BMDM (data not shown), and bone development in Ajuba null
mice was not abnormal (data not shown). Ajuba-related
LIMD1 also interacts with p62. LIMD1 was originally identified as an open reading frame present on a segment of chromosome 3 deleted in some cervical cancers (20). Little else is
known about LIMD1 cell biology or function. Interestingly,
LIMD1 expression, like p62, is upregulated during RANKLinduced osteoclast differentiation of BMDM (8; Y. Feng and
G. Longmore, unpublished). Therefore, it will be interesting to
determine whether genetic ablation of LIMD1 affects bone
metabolism through modulation of IL-1, TNF, and RANKL
signaling pathways. Finally, residual NF-B activity in Ajuba
null MEFs and lungs may reflect the presence of LIMD1 in
these cells and/or tissues.
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